Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON

BACKGROUND: Atherogenic dyslipidemia (AD), characterized by increased concentrations of apolipoprotein B (ApoB)-containing particles, is often present in individuals with type 2 diabetes mellitus (T2DM). Non-high-density lipoprotein cholesterol (non-HDL-C), cholesterol transported by apolipoprotein...

Descripción completa

Detalles Bibliográficos
Autores principales: Lorenzatti, Alberto J., Monsalvo, Maria Laura, López, J. Antonio G., Wang, Huei, Rosenson, Robert S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8091704/
https://www.ncbi.nlm.nih.gov/pubmed/33941192
http://dx.doi.org/10.1186/s12933-021-01287-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8091704/
https://www.ncbi.nlm.nih.gov/pubmed/33941192
http://dx.doi.org/10.1186/s12933-021-01287-6

Ejemplares similares